Astellas looks to tap Indian growth with new subsidiary
This article was originally published in Scrip
Executive Summary
Astellashas set up a new commercial subsidiary in India to tap into the growth it foresees in Asia's fourth-largest pharmaceutical market, hot on the heels of peer Daiichi Sankyo's just-completed acquisition of Ranbaxy.